Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from colorectal and appendiceal cancer: five-years of experience

https://doi.org/10.4081/joper.2016.3

Authors

  • Giulia Montori | giulia.montori@gmail.com Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Paola Fugazzola Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Marco Ceresoli Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Andrea Gianatti Department of Anatomical Pathology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Vincenzo Gatti Department of Pharmacology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Gian Carlo Taddei Department of Pharmacology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Federico Coccolini Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Roberto Manfredi Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Luca Ansaloni Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Abstract

An increasing promising evidence support the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinosis from colorectal cancer (CRC) and appendiceal cancer (AC). In our institute 18 patients with CRC and 4 patients with AC undergone to CRS and HIPEC were retrospectively analyzed from 2011 to 2016. Patients and tumor characteristics were analyzed. Overall survival and disease free survival were analyzed with Kaplan-Meier curves and log-rank testing. Median disease free survival (DFS) is 20.5 and 31.4 months in CRC and AC respectively (P=0.76). Instead mean overall survival is 37.8 and 44.6 months in CRC and AC group respectively (P=0.46). Primary CRC have an improved DFS compared patients with relapse tumor (45.2 versus 19.4 months) (P=0.037). Comparing with conventional chemotherapy regimens CRS and HIPEC from CRC and AC may obtain a better disease control particularly when a complete cytoreduction is achieved. The combined treatment can have a potential curative intent.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biography

Giulia Montori, Department of General and Emergency Surgery, Papa Giovanni XXIII Hospital, Bergamo
Emergency and Trauma Dept.
Published
2016-06-14
Info
Issue
Section
Original Articles
Keywords:
Colorectal and appendiceal cancer, high-grade non-mucinous carcinoma., hyperthermic intraperitoneal chemotherapy, cytoreductive surgery, peritoneal mucinous carcinomatosis, high-grade non-mucinous carcinoma
Statistics
  • Abstract views: 710

  • PDF: 556
How to Cite
1.
Montori G, Fugazzola P, Ceresoli M, Gianatti A, Gatti V, Taddei GC, Coccolini F, Manfredi R, Ansaloni L. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from colorectal and appendiceal cancer: five-years of experience. J Peritoneum [Internet]. 2016Jun.14 [cited 2020Sep.22];1(1). Available from: http://www.jperitoneum.org/index.php/joper/article/view/3

Most read articles by the same author(s)

1 2 > >>